_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The deal signals a clear push to expand access to care in underserved regions
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The transition from an outsourced MRI model to an in-house facility marks more than an infrastructure upgrade
Subscribe To Our Newsletter & Stay Updated
